Semaglutide is a synthetic 31-amino-acid peptide designed as a long-acting analog of the endogenous incretin hormone GLP-1 (glucagon-like peptide-1). It is sold as Ozempic (injection, type 2 diabetes indication), Wegovy (injection, obesity indication), and Rybelsus (oral tablet, diabetes). The molecule is identical in all three products; the dosing schedule and approved indication differ. Semaglutide and its successor tirzepatide have, within a few years, produced the most substantial advance in obesity pharmacotherapy in the history of the field. The long-term story — durability, side effect profile over decades, costs, and what happens on discontinuation — is still being written.
At a glance
What it does
Semaglutide activates the GLP-1 receptor expressed on pancreatic beta cells, gastrointestinal tract, hypothalamus, and several other tissues. The clinically relevant effects are glucose-dependent insulin secretion (beta cells release more insulin when glucose is high and not when it is low, reducing hypoglycemia risk compared with sulfonylureas), suppression of glucagon release from alpha cells, delayed gastric emptying (food stays in the stomach longer, promoting satiety), and central effects on appetite through hypothalamic GLP-1 receptors.
The net clinical effect is reduced food intake, reduced postprandial glucose spikes, improved HbA1c in diabetes, and substantial weight loss. In the STEP trials for obesity, semaglutide at 2.4 mg weekly produced mean weight loss around 15% of body weight at 68 weeks — roughly triple what prior obesity drugs achieved and comparable to what conventional bariatric surgery produced in the first year. In the SUSTAIN trials for diabetes, semaglutide produced HbA1c reductions around 1.5-2% and weight loss around 4-6 kg depending on dose.
Beyond glucose and weight, recent trials have shown cardiovascular benefit in overweight/obese patients without diabetes (SELECT trial — 20% reduction in major adverse cardiovascular events), kidney benefit, and emerging suggestions of benefits in sleep apnea, MASLD, and addiction behaviors. The "food noise" phenomenon — users reporting that obsessive thoughts about eating simply switch off — is consistent with central effects on reward and appetite circuits and has sparked interest in trials for alcohol use disorder and other addictions.
How it works
Endogenous GLP-1 is released from intestinal L-cells after meals and contributes to postprandial insulin release, but it has a half-life of only 2 minutes because of rapid degradation by DPP-4. Semaglutide was engineered for stability by modifying two amino acid positions to resist DPP-4 cleavage and by attaching a fatty acid side chain that binds albumin, extending the effective half-life to about 7 days. This allows weekly subcutaneous injection with relatively stable plasma levels — a major convenience advantage over earlier GLP-1 agonists that required daily or multiple-daily dosing.
At the GLP-1 receptor, semaglutide is a full agonist. Activation produces downstream effects through cAMP-mediated pathways. In beta cells, this amplifies glucose-stimulated insulin release. In the stomach, it slows gastric emptying by vagal and direct effects on gastric smooth muscle — the single biggest driver of nausea side effects and probably one of the major satiety mechanisms. In the brain, GLP-1 receptors in hypothalamic arcuate nucleus, area postrema, and several cortical and limbic areas modulate food intake and reward response.
The slow gastric emptying is a double-edged sword. It reduces postprandial glucose excursions and promotes satiety, but it is also why nausea, vomiting, and early satiety are the most common side effects. Dose titration over weeks to months is standard practice specifically to give the gastric system time to adapt. The degree of gastric delay correlates with both satiety benefit and nausea — some of the same mechanism doing both jobs.
Levels & ranges
Semaglutide is dosed by the milligram weekly (injectable) or daily (oral, at much higher doses due to low bioavailability through gastric epithelium). Injectable starting dose is typically 0.25 mg weekly for 4 weeks, titrating up to 0.5, 1.0, 1.7, and up to 2.4 mg weekly for obesity or 2.0 mg weekly for diabetes. Slower titration reduces GI side effect severity.
There is no clinically relevant blood level monitoring — doses are set by indication and response, not by serum levels. What gets monitored in practice is weight trajectory, HbA1c, fasting glucose, and symptom burden. Most weight loss occurs in the first 6-12 months; weight tends to plateau as caloric intake stabilizes at a new lower level and energy expenditure drops somewhat (a normal adaptive response to weight loss, not a semaglutide-specific problem).
Discontinuation data matters. In the STEP 4 extension trial, patients who stopped semaglutide after a year regained about two-thirds of lost weight within another year. This is not unique to semaglutide — it is the pattern for almost every weight loss intervention except bariatric surgery — but it has practical implications. For most users, the effective treatment plan is long-term or indefinite use, not a "course" that ends with the weight maintained on its own.
When it goes wrong
Nausea, vomiting, diarrhea, and constipation are the dominant side effects, affecting roughly 30-50% of users at some point, especially during dose escalation. Most tolerate after titration, but some do not and discontinue. Gastroparesis (severely delayed gastric emptying) is a rare but documented complication and has become the subject of ongoing regulatory and legal attention. Risk is higher in patients with preexisting gastroparesis or significant autonomic dysfunction.
Rare but more serious adverse events include pancreatitis (elevated risk signal in postmarketing data, though not clearly elevated in large RCT pooled analyses), gallbladder disease (rapid weight loss is a classic gallstone risk factor, and semaglutide inherits this), medullary thyroid carcinoma concern from rodent studies (contraindicated in patients with personal or family history of MTC or MEN 2), and a small signal for acute kidney injury in severely dehydrated patients from vomiting.
Muscle loss accompanies weight loss on semaglutide, as it does with most weight loss interventions. Estimates suggest 25-40% of lost weight may come from lean mass in unsupervised use. This can be substantially mitigated by resistance training and adequate protein intake, which is why any sensible prescribing pattern includes those recommendations rather than treating weight loss as purely a caloric issue.
The "Ozempic face" phenomenon — gaunt appearance from rapid subcutaneous fat loss in the face — is a cosmetic effect of substantial weight loss, not a unique drug toxicity. Any intervention producing 15-20% weight loss will produce similar facial changes. Less discussed but more medically relevant, rapid weight loss alters thyroid hormone requirements in treated hypothyroidism, antihypertensive needs, diabetes medication requirements, and sometimes mood — clinicians should be watching for all of these during active weight loss phases.
Long-term safety beyond 5-7 years is unknown. The drug has been in wide use for diabetes since 2017 and for obesity since 2021. The cardiovascular and kidney outcome trials are reassuring at their specific durations. Whether 15-20 year use produces unexpected signals remains to be seen, and the honest statement to patients is that they are in the early majority of a rapidly expanding user population, not a clinically unknown territory but not a mature one either.
Interactions
Delayed gastric emptying affects absorption of other drugs, particularly oral medications with narrow therapeutic windows. Absorption of oral contraceptives, thyroid hormone, and various others can be modestly delayed or altered. This usually does not require intervention but should be known.
Combination with other GLP-1 agonists is not indicated and has no established benefit. Combination with SGLT2 inhibitors and metformin in diabetes is standard and synergistic. Combination with insulin requires careful insulin dose reduction to avoid hypoglycemia as glucose control improves. Combination with sulfonylureas is similar — hypoglycemia risk rises as sulfonylurea effect amplifies on reduced-demand metabolism.
Alcohol use on semaglutide is an active area of research. Multiple early reports suggest semaglutide reduces alcohol cravings and consumption, and formal trials are underway for alcohol use disorder. The mechanism is probably GLP-1 receptor effects on mesolimbic reward circuits. This is also why emerging trials are investigating semaglutide and related GLP-1 agonists in compulsive eating, gambling, and substance use disorders.
Cost and access dominate the practical interaction picture in the US. US list prices of roughly $900-1400/month, with insurance coverage patchy for obesity indication, have produced a large compounded-semaglutide market during shortage periods. Compounded versions from sterile compounding pharmacies are legal during declared shortages but introduce additional variables around purity, concentration accuracy, and clinical oversight. The FDA declared semaglutide off the shortage list in 2025, which has significantly restricted compounded sources in the US. Gray-market "research peptide" semaglutide is not a safe source.
Honest take
GLP-1 agonists are the most important obesity pharmacotherapy advance in decades and — unlike prior drugs in this space — the effect sizes are large enough to matter metabolically and not just statistically. They are not cheat codes, they are real drugs with real side effects and a real, currently indefinite, treatment duration. The reflexive moralizing from some fitness culture voices ("just eat less and move more") ignores that chronic obesity is not purely a discipline problem — appetite regulation is a biological system, and these drugs modify that system in ways willpower cannot match. The flip side is that using them without concurrent resistance training and adequate protein is a recipe for losing substantial muscle alongside fat, and stopping the drug without infrastructure for sustained behavior change tends to produce weight regain. The ideal use case is the severely insulin-resistant or obese patient who cannot achieve meaningful weight loss with lifestyle alone; the clearly bad use case is someone already reasonably lean chasing cosmetic changes through a gray-market supply. The middle ground — moderately overweight patients with metabolic risk factors — is where most actual prescribing happens, and the evidence there is favorable but incomplete.
Sources
- Wilding et al., STEP 1 trial, NEJM (2021) — the landmark obesity efficacy trial establishing ~15% mean weight loss at 68 weeks.
- Lincoff et al., SELECT trial, NEJM (2023) — cardiovascular outcomes in overweight/obese patients without diabetes, establishing semaglutide's cardiovascular benefit.
- Marso et al., SUSTAIN-6 trial, NEJM (2016) — earlier cardiovascular outcomes in type 2 diabetes.
- Rubino et al., STEP 4 trial, JAMA (2021) — discontinuation study showing substantial weight regain after stopping treatment.